Entecavir, a guanosine nucleoside analogue with activity against HBV reverse transcriptase.
Entecavir inhibits all three activities of the HBV reverse transcriptase: (1) base priming, (2) reverse transcription of the negative strand from the pregenomic messenger RNA, and (3) synthesis of the positive strand of HBV DNA.
|Product Name||IRETAVIR 0.5|
|Generic Name||Entecavir USP 0.5 mg|
|FDA Approved Indications||Entecavir is indicated for the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.|
|Packaging||IRETAVIR 0.5 mg tablets are supplied in alu alu blister. Each commercial box IRETAVIR contain 10’s (1X10’s) in alu- alu blister.|
|PI||IRETAVIR 0.5 (PDF)|